A >10% to <5% reduction in liver fat has been demonstrated in people with obesity following bariatric surgery (Luo et al., 2018), while treatment with GLP-1 receptor agonists has shown to reduce liver fat, VAT, and associated metabolic markers such as hyperglycaemia (Flint et al., 2021; Gadde and Heymsfield, 2021). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.